Neo Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.09 Cr
as on 11-12-2024
- Paid Up Capital ₹ 6.02 M
as on 11-12-2024
- Company Age 74 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5,097.31 Cr
as on 11-12-2024
- Satisfied Charges ₹ 1,253.00 Cr
as on 11-12-2024
- Revenue -35.62%
(FY 2023)
- Profit -53.30%
(FY 2023)
- Ebitda -51.82%
(FY 2023)
- Net Worth 3.86%
(FY 2023)
- Total Assets 7.40%
(FY 2023)
About Neo Pharma
The Corporate was formerly known as Neo-Pharma Private Limited. The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.09 Cr and a paid-up capital of Rs 6.02 M.
The company currently has active open charges totaling ₹5,097.31 Cr. The company has closed loans amounting to ₹1,253.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jayant Oswal, Venkatesh Bhandare, and Bajrang Bararia serve as directors at the Company.
- CIN/LLPIN
U24239MH1950PTC008016
- Company No.
008016
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 1950
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neo Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayant Oswal  | Director | 28-Mar-2015 | Current |
| Venkatesh Bhandare | Director | 30-Nov-2017 | Current |
| Bajrang Bararia | Director | 12-Mar-2021 | Current |
Financial Performance of Neo Pharma.
Neo Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 35.62% decrease. The company also saw a substantial fall in profitability, with a 53.3% decrease in profit. The company's net worth moved up by a moderate rise of 3.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neo Pharma?
In 2023, Neo Pharma had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Kalpataru Constructions (Poona) Private LimitedActive 17 years 7 months
Jayant Oswal and Venkatesh Bhandare are mutual person
- Kalpataru Homes Private LimitedActive 16 years 4 months
Jayant Oswal and Bajrang Bararia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 Apr 2021 | ₹4,572.31 Cr | Open |
Others Creation Date: 31 Mar 2021 | ₹175.00 Cr | Open |
Others Creation Date: 11 Nov 2020 | ₹10.00 Cr | Open |
How Many Employees Work at Neo Pharma?
Neo Pharma has a workforce of 43 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neo Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neo Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
